Relationships between Alanine Aminotransferase Levels, Abnormal Liver Echogenicity, and Metabolic Syndrome

References

1. ↵
   Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–28.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998; 15: 539–53.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735–52.

   OpenUrlFREE Full Text
5. ↵
   Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27: 1182–6.

   OpenUrlAbstract/FREE Full Text
6. ↵
   Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006; 105: 626–35.

   OpenUrlPubMedWeb of Science
7. ↵
   Ohlson LO, Larsson B, Bjorntorp P, et al. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988; 31: 798–805.

   OpenUrlPubMedWeb of Science
8. ↵
   Mainous AG 3rd, Diaz VA, King DE, Everett CJ, Player MS. The relationship of hepatitis antibodies and elevated liver enzymes with impaired fasting glucose and undiagnosed diabetes. J Am Board Fam Med 2008; 21: 497–503.

   OpenUrlAbstract/FREE Full Text
9. ↵
   Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844–50.

   OpenUrlAbstract/FREE Full Text
10. ↵
    Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med 2002; 21: 1023–32.

    OpenUrlAbstract/FREE Full Text
11. ↵
    Vehmas T, Kaukiainen A, Immonen-Raiha P, Lohman M, Luoma K. Liver echogenicity: relation to systemic blood pressure and other components of the metabolic syndrome. Ultrasound Med Biol 2005; 31: 293–9.

    OpenUrlPubMed
12. ↵
    Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292: 13–5.

    OpenUrlAbstract/FREE Full Text
13. ↵
    Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004; 53: 2855–60.

    OpenUrlAbstract/FREE Full Text
14. ↵
    Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB, Haffner SM. Liver markers and development of the metabolic syndrome. Diabetes 2005; 54: 3140–7.

    OpenUrlAbstract/FREE Full Text
15. ↵
    Kim HC, Choi SH, Shin HW, et al. Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World J Gastroenterol 2005; 11: 5314–21.

    OpenUrlPubMed
16. ↵
    Shen YH, Yang WS, Lee TH, Lee LT, Chen CY, Huang KC. Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults. Obes Res 2005; 13: 1238–45.

    OpenUrlPubMedWeb of Science
17. ↵
    Olynyk JK, Knuiman MW, Divitini ML, Davis TME, Beilby J, Hung J. Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol 2009; 104: 1715–22.

    OpenUrlCrossRefPubMed
18. ↵
    Chen DS. Hepatocellular carcinoma in Taiwan. Hepatol Res 2007; 37: S101–S5.

    OpenUrlCrossRefPubMed
19. ↵
    Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960–7.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286–92.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–23.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27–38.

    OpenUrlAbstract/FREE Full Text
23. ↵
    Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–95.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43: 26–31.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    Hsu CS, Kao JH. Hepatitis C infection and metabolic syndrome. J Formos Med Assoc 2010; 109: 403–7.

    OpenUrlPubMed
26. ↵
    Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008; 47: 2127–33.

    OpenUrlCrossRefPubMedWeb of Science